Optimising preoperative systemic therapy for breast cancer

Author(s):
Charehbili, A.
Published
2015
Publication type
Doctoral Thesis

Abstract

This thesis was divided in two parts. Part I demonstrated benefit of zoledronic acid addition to chemotherapy in terms of pathological response in postmenopausal women. Part II is all about neoadjuvant endocrine therapy, and discusses the optimal duration of this treatment and the information on treatment efficacy that aromatase-inhibitor specific adverse events may provide.

Zoledronic acidAromatase inhibitorsBisphosphonatesNeoadjuvanChemotherapyBreast cancer
Defense date
2015-09-16
Language
English
Supervisor(s)
Velde, C.J.H. van de; Nortier, J.W.R.
Advisor(s)
Kroep, J.R.
Qualification
Ph.D.
Degree granting institution
Faculty of Medicine (LUMC), Leiden University, Leiden
hdl
1887/35283
ISBN(s)
9789462330191

Funding

Sponsorship
The printing of this thesis was made possible by the departments of Medical Oncology and Surgery of the Leiden Universtity Medical Center, Boehringer Ingelheim, Chipsoft, Philips, Novartis, Pfizer and Galephar.